Celltrion (068270 KS): Stellar 3Q Result; Poised for Accelerated Growth on Expanding Portfolio
Celltrion reported YoY and sequential growth in all key parameters in 3Q powered by high-margin new products. In 4Q25, Celltrion is expected to...
334 Views
Primer: Celltrion (068270 KP) - Nov 2025
Celltrion is strategically transitioning from a biosimilar powerhouse to a global innovative biopharmaceutical company, underscored by the...
161 Views
Celltrion (068270 KS/Buy)Cost Ratio Continues to Improve
Our target price for Celltrion is based on our 12-month forward EBITDA estimate of W1.87tr and a target EV/EBITDA of 27x.
184 Views
Celltrion Inc Update – Is It Time to Go Long (068270 KS)
Celltrion Inc has underperformed due to biosimilar hype, but outlook for next 5 years is promising with revenue target market value expected to...
553 Views
Celltrion Inc (068270 KS): Acquiring US Manufacturing Plant To Alleviate Tariff Impact
Celltrion is acquiring Eli Lilly’s New Jersey biopharmaceutical production plant for KRW460B. The company also plans to expand capacity of the...
358 Views